Moderna (MRNA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Moderna (MRNA)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Key Insights
Critical company metrics and information
Share Price
$45.65Market Cap
$17.57 BillionTotal Outstanding Shares
384.82 Million SharesTotal Employees
5,600Dividend
No dividendIPO Date
December 7, 2018SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.modernatx.com
Historical Stock Splits
If you bought 1 share of MRNA before July 22, 2010, you'd have 0.00 shares today.
Execution Date | Split Amount |
---|---|
August 3, 2017 | 1-for-10 (Reverse Split) |
December 23, 2011 | 1-for-10 (Reverse Split) |
July 22, 2010 | 1-for-4 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $1.95 Billion |
Net Cash Flow | $-1.31 Billion |
Net Cash Flow From Operating Activities | $-3.21 Billion |
Net Cash Flow, Continuing | $-1.31 Billion |
Net Cash Flow From Financing Activities | $-50.00 Million |
Net Cash Flow From Operating Activities, Continuing | $-3.21 Billion |
Net Cash Flow From Financing Activities, Continuing | $-50.00 Million |
Net Cash Flow From Investing Activities | $1.95 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Equity Method Investments | $-62.00 Million |
Income/Loss From Continuing Operations After Tax | $-2.22 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $-2.22 Billion |
Research and Development | $4.83 Billion |
Cost Of Revenue | $1.65 Billion |
Net Income/Loss Attributable To Parent | $-2.22 Billion |
Income/Loss From Continuing Operations Before Tax | $-2.35 Billion |
Operating Income/Loss | $-2.69 Billion |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income/Loss Before Equity Method Investments | $-2.29 Billion |
Diluted Average Shares | $782.00 Million |
Other Operating Expenses | $1.29 Billion |
Basic Average Shares | $768.00 Million |
Costs And Expenses | $7.77 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Benefits Costs and Expenses | $7.43 Billion |
Basic Earnings Per Share | $-5.82 |
Diluted Earnings Per Share | $-5.82 |
Revenues | $5.08 Billion |
Gross Profit | $3.43 Billion |
Operating Expenses | $6.12 Billion |
Net Income/Loss | $-2.22 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income Tax Expense/Benefit | $-129.00 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities And Equity | $15.80 Billion |
Noncurrent Liabilities | $1.68 Billion |
Other Current Liabilities | $1.58 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities | $3.88 Billion |
Noncurrent Assets | $6.14 Billion |
Equity | $11.93 Billion |
Wages | $244.00 Million |
Inventory | $412.00 Million |
Current Liabilities | $2.20 Billion |
Current Assets | $9.67 Billion |
Accounts Payable | $373.00 Million |
Other Current Assets | $9.25 Billion |
Assets | $15.80 Billion |
Equity Attributable To Parent | $11.93 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Moderna (MRNA)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.